Aberdeen Group plc Buys 448,475 Shares of ProQR Therapeutics N.V. $PRQR

Aberdeen Group plc raised its holdings in ProQR Therapeutics N.V. (NASDAQ:PRQR) by 24.2% during the 3rd quarter, HoldingsChannel reports. The institutional investor owned 2,298,823 shares of the biopharmaceutical company’s stock after purchasing an additional 448,475 shares during the period. Aberdeen Group plc’s holdings in ProQR Therapeutics were worth $4,896,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors also recently modified their holdings of PRQR. Affinity Asset Advisors LLC lifted its position in ProQR Therapeutics by 6.5% during the 2nd quarter. Affinity Asset Advisors LLC now owns 3,499,512 shares of the biopharmaceutical company’s stock worth $7,139,000 after buying an additional 215,000 shares in the last quarter. Sio Capital Management LLC raised its stake in shares of ProQR Therapeutics by 1.0% in the 2nd quarter. Sio Capital Management LLC now owns 2,075,139 shares of the biopharmaceutical company’s stock valued at $4,233,000 after purchasing an additional 20,546 shares during the period. BNP Paribas Financial Markets boosted its position in ProQR Therapeutics by 28.4% during the 2nd quarter. BNP Paribas Financial Markets now owns 121,494 shares of the biopharmaceutical company’s stock worth $248,000 after acquiring an additional 26,893 shares during the last quarter. Bank of America Corp DE increased its stake in ProQR Therapeutics by 25.7% in the 2nd quarter. Bank of America Corp DE now owns 119,198 shares of the biopharmaceutical company’s stock valued at $243,000 after buying an additional 24,347 shares during the last quarter. Finally, Jane Street Group LLC raised its holdings in ProQR Therapeutics by 699.3% during the first quarter. Jane Street Group LLC now owns 91,120 shares of the biopharmaceutical company’s stock worth $121,000 after acquiring an additional 79,720 shares in the last quarter. Institutional investors own 32.65% of the company’s stock.

ProQR Therapeutics Stock Performance

Shares of PRQR stock opened at $1.44 on Friday. The company has a market capitalization of $151.50 million, a price-to-earnings ratio of -3.06 and a beta of 0.20. The company has a 50-day simple moving average of $1.79 and a 200 day simple moving average of $2.11. ProQR Therapeutics N.V. has a 52 week low of $1.07 and a 52 week high of $3.10.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on PRQR shares. Chardan Capital restated a “buy” rating and set a $4.00 target price on shares of ProQR Therapeutics in a report on Tuesday, November 4th. Weiss Ratings reissued a “sell (d-)” rating on shares of ProQR Therapeutics in a research report on Thursday, January 22nd. Finally, Zacks Research upgraded shares of ProQR Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Thursday, November 13th. Seven research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, ProQR Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $7.14.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company’s pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.